Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Cash & Equivalents (2021 - 2025)

Verrica Pharmaceuticals has reported Cash & Equivalents over the past 5 years, most recently at $30.1 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $30.1 million for Q4 2025, down 34.93% from a year ago — trailing twelve months through Dec 2025 was $30.1 million (down 34.93% YoY), and the annual figure for FY2025 was $30.1 million, down 34.93%.
  • Cash & Equivalents for Q4 2025 was $30.1 million at Verrica Pharmaceuticals, up from $21.1 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for VRCA hit a ceiling of $84.3 million in Q3 2023 and a floor of $15.4 million in Q2 2025.
  • Median Cash & Equivalents over the past 5 years was $33.4 million (2022), compared with a mean of $39.1 million.
  • Biggest five-year swings in Cash & Equivalents: soared 159.6% in 2023 and later tumbled 72.72% in 2024.
  • Verrica Pharmaceuticals' Cash & Equivalents stood at $15.8 million in 2021, then soared by 117.58% to $34.3 million in 2022, then surged by 102.92% to $69.5 million in 2023, then crashed by 33.38% to $46.3 million in 2024, then tumbled by 34.93% to $30.1 million in 2025.
  • The last three reported values for Cash & Equivalents were $30.1 million (Q4 2025), $21.1 million (Q3 2025), and $15.4 million (Q2 2025) per Business Quant data.